PrecisemAb Successfully Develops Universal Antibody Lock to Overcome the Trade Off Between Efficacy and Toxicity in Cancer Therapy
We sincerely thank ESGtimes – Sustainable Times for the interview and in-depth feature, which allows more…
Lock antibody
Read MorePrecisemAb Successfully Develops Universal Antibody Lock to Overcome the Trade Off Between Efficacy and Toxicity in Cancer Therapy
PrecisemAb Awarded the Title of “2025 Emerging High-Potential Startup”
PrecisemAb Biotech has been honored by the Small and Medium Enterprise Administration, Ministry of Economic Affairs,…
PrecisemAb Publishes New Research on Tumor-Selective Activation Antibodies in the International Journal of Biological Macromolecules
We are pleased to share that our latest research article,“Development of a tumor-region-selective activation monoclonal antibody…
Congratulations on PrecisemAb’s winning of Innovative Enterprise Award held by Ministry of Economics Affairs.
This award recognizes our outstanding performance as a startup company and also shows our great market…